Application of vitamin D and derivatives in hematological malignancies

Cancer Letters

Volumn 319, Issue 1, 2012, Pages 8-22

  Kim, Minji ^a   Mirandola, Leonardo ^a,b   Pandey, Apurva ^a   Nguyen, Diane D ^a   Jenkins, Marjorie R ^a,b   Turcel, Meryem ^a   Cobos, Everardo ^a,b   Chiriva Internati, Maurizio ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Clinical trials; Hematological malignancies; Intracellular kinases; Multiple myeloma; Vitamin D

Indexed keywords

ALFACALCIDOL; ALITRETINOIN; ALPHA INTERFERON; ALPHA TOCOPHEROL; AURANOFIN; BUFALIN; CALCITRIOL; CAMPTOTHECIN; CAPSAICIN; CARNOSIC ACID; COLECALCIFEROL; CURCUMIN; CYTARABINE; DEXAMETHASONE; DOXERCALCIFEROL; EVEROLIMUS; GINSENG EXTRACT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; INDIRUBIN; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; RETINOIC ACID; SEOCALCITOL; SILIBININ; TIOGUANINE; UNINDEXED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER REGRESSION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERCALCEMIA; LEUKEMIA CELL; LOW DRUG DOSE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RHEUMATOID ARTHRITIS; SHORT SURVEY; SUN EXPOSURE; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN D RESPONSIVE ELEMENT;

EID: 84862809395     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.026     Document Type: Review

References (128)

1. Miller J., Gallo R.L. Vitamin D and innate immunity. Dermatol. Ther. 2010, 23:13-22.
2. Baeke F., Gysemans C., Korf H., Mathieu C. Vitamin D insufficiency: implications for the immune system. Pediatr. Nephrol. 2010.
3. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., Willett W.C. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J. Natl. Cancer. Inst. 2006, 98:451-459.
4. Miyaura C., Abe E., Kuribayashi T., Tanaka H., Konno K., Nishii Y., Suda T. 1 alpha,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem. Biophys. Res. Commun. 1981, 102:937-943.
5. Mangelsdorf D.J., Koeffler H.P., Donaldson C.A., Pike J.W., Haussler M.R. 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J. Cell. Biol. 1984, 98:391-398.
6. Munker R., Norman A., Koeffler H.P. Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells. J. Clin. Invest. 1986, 78:424-430.
7. Brown G., Choudhry M.A., Durham J., Drayson M.T., Michell R.H. Monocytically differentiating HL60 cells proliferate rapidly before they mature. Exp. Cell Res. 1999, 253:511-518.
8. Rots N.Y., Iavarone A., Bromleigh V., Freedman L.P. Induced differentiation of U937 cells by 1,25-dihydroxyvitamin D3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 1999, 93:2721-2729.
9. Studzinski G.P., Bhandal A.K., Brelvi Z.S. Cell cycle sensitivity of HL-60 cells to the differentiation-inducing effects of 1-alpha, 25-dihydroxyvitamin D3. Can. Res. 1985, 45:3898-3905.
10. Humeniuk-Polaczek R., Marcinkowska E. Impaired nuclear localization of vitamin D receptor in leukemia cells resistant to calcitriol-induced differentiation. J. Steroid Biochem. Mol. Biol. 2004, 88:361-366.
11. Carlberg C., Bendik I., Wyss A., Meier E., Sturzenbecker L.J., Grippo J.F., Hunziker W. Two nuclear signalling pathways for vitamin D. Nature 1993, 361:657-660.
12. Gocek E., Kielbinski M., Marcinkowska E. Activation of intracellular signaling pathways is necessary for an increase in VDR expression and its nuclear translocation. FEBS Lett. 2007, 581:1751-1757.
13. Bhatia M., Kirkland J.B., Meckling-Gill K.A. Monocytic differentiation of acute promyelocytic leukemia cells in response to 1,25-dihydroxyvitamin D3 is independent of nuclear receptor binding. J. Biol. Chem. 1995, 270:15962-15965.
14. Hughes P.J., Marcinkowska E., Gocek E., Studzinski G.P., Brown G. Vitamin D3-driven signals for myeloid cell differentiation - implications for differentiation therapy. Leuk. Res. 2010, 34:553-565.
15. Solomon D.H., O'Driscoll K., Sosne G., Weinstein I.B., Cayre Y.E. 1 alpha,25-dihydroxyvitamin D3-induced regulation of protein kinase C gene expression during HL-60 cell differentiation. Cell Growth Differ. 1991, 2:187-194.
16. Aihara H., Asaoka Y., Yoshida K., Nishizuka Y. Sustained activation of protein kinase C is essential to HL-60 cell differentiation to macrophage. Proc. Natl. Acad. Sci. USA 1991, 88:11062-11066.
17. Kharbanda S., Saleem A., Emoto Y., Stone R., Rapp U., Kufe D. Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells. J. Biol. Chem. 1994, 269:872-878.
18. Okazaki T., Bielawska A., Bell R.M., Hannun Y.A. Role of ceramide as a lipid mediator of 1 alpha, 25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J. Biol. Chem. 1990, 265:15823-15831.
19. Okazaki T., Bielawska A., Domae N., Bell R.M., Hannun Y.A. Characteristics and partial purification of a novel cytosolic, magnesium-independent, neutral sphingomyelinase activated in the early signal transduction of 1 alpha, 25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J. Biol. Chem. 1994, 269:4070-4077.
20. Hmama Z., Nandan D., Sly L., Knutson K.L., Herrera-Velit P., Reiner N.E. 1alpha, 25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J. Exp. Med. 1999, 190:1583-1594.
21. Zhang Y., Zhang J., Studzinski G.P. AKT pathway is activated by 1,25-dihydroxyvitamin D3 and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells. Cell cycle 2006, 5:447-451.
22. Wang J., Zhao Y., Kauss M.A., Spindel S., Lian H. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Eur. J. Cell Biol. 2009, 88:103-115.
23. Wang Q., Wang X., Studzinski G.P. Jun N-terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25-dihydroxyvitamin D3. J. Cell Biochem. 2003, 89:1087-1101.
24. Chen F., Wang Q., Wang X., Studzinski G.P. Up-regulation of Egr1 by 1, 25-dihydroxyvitamin D3 contributes to increased expression of p35 activator of cyclin-dependent kinase 5 and consequent onset of the terminal phase of HL60 cell differentiation. Cancer Res. 2004, 64:5425-5433.
25. Chen-Deutsch X., Garay E., Zhang J., Harrison J.S., Studzinski G.P. C-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. Leuk. Res. 2009, 33:1372-1378.
26. Marcinkowska E., Garay E., Gocek E., Chrobak A., Wang X., Studzinski G.P. Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3. Exp. Cell Res. 2006, 312:2054-2065.
27. Wang X., Wang T.T., White J.H., Studzinski G.P. Induction of kinase suppressor of RAS-1(KSR-1) gene by 1,alpha 25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region. Oncogene 2006, 25:7078-7085.
28. Wang Q.M., Jones J.B., Studzinski G.P. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res. 1996, 56:264-267.
29. Wang X., Studzinski G.P. Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells. J. Cell Biochem. 2001, 80:471-482.
30. Wang X., Rao J., Studzinski G.P. Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D(3)-induced differentiation of human leukemia HL60 cells. Exp. Cell Res. 2000, 258:425-437.
31. Suzuki T., Koyama Y., Hayakawa S., Munakata H., Isemura M. 1,25-Dihydroxyvitamin D3 suppresses exportin expression in human promyelocytic leukemia HL-60 cells. Biomed. Res. 2006, 27:89-92.
32. Suzuki T., Koyama Y., Ichikawa H., Tsushima K., Abe K., Hayakawa S., Kuruto-Niwa R., Nozawa R., Isemura M. 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells. Cell Struct. Funct. 2005, 30:1-6.
33. Wang J., Lian H., Zhao Y., Kauss M.A., Spindel S. Vitamin D3 induces autophagy of human myeloid leukemia cells. J. Biol. Chem. 2008, 283:25596-25605.
34. Wang X., Studzinski G.P. Antiapoptotic action of 1,25-dihydroxyvitamin D3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome c. Exp. Cell Res. 1997, 235:210-217.
35. Kizildag S., Ates H. Treatment of K562 cells with 1,25-dihydroxyvitamin D(3) induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCL(XL), and p21. Ann. Hematol. 2009.
36. Wietrzyk J., Filip B., Milczarek M., Klopotowska D., Maciejewska M., Dabrowska K., Kurzepa A., Dzimira S., Madej J., Kutner A. The influence of 1,25-dihydroxyvitamin D3 and 1,24-dihydroxyvitamin D3 on alphavbeta3 integrin expression in cancer cell lines. Oncol. Rep. 2008, 20:941-952.
37. Gombart A.F., Borregaard N., Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005, 19:1067-1077.
38. Camagna A., Testa U., Masciulli R., Barberi T., Samoggia P., Tritarelli E., Pustorino E., Cipollone L., Ciancio L., del Duca P., et al. The synergistic effect of simultaneous addition of retinoic acid and vitamin D3 on the in-vitro differentiation of human promyelocytic leukemia cell lines could be efficiently transposed in vivo. Med. Hypo. 1998, 50:253-257.
39. Elstner E., Linker-Israeli M., Le J., Umiel T., Michl P., Said J.W., Binderup L., Reed J.C., Koeffler H.P. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid. J. Clin. Invest. 1997, 99:349-360.
40. Bastie J.N., Balitrand N., Guillemot I., Chomienne C., Delva L. Cooperative action of 1alpha, 25-dihydroxyvitamin D3 and retinoic acid in NB4 acute promyelocytic leukemia cell differentiation is transcriptionally controlled. Exp. Cell Res. 2005, 310:319-330.
41. Defacque H., Piquemal D., Basset A., Marti J., Commes T. Transforming growth factor-beta1 is an autocrine mediator of U937 cell growth arrest and differentiation induced by vitamin D3 and retinoids. J. Cell Physiol. 1999, 178:109-119.
42. Makishima M., Shudo K., Honma Y. Greater synergism of retinoic acid receptor (RAR) agonists with vitamin D3 than that of retinoid X receptor (RXR) agonists with regard to growth inhibition and differentiation induction in monoblastic leukemia cells. Biochem. Pharmacol. 1999, 57:521-529.
43. Park S.J., Kim M., Kim N.H., Oh M.K., Cho J.K., Jin J.Y., Kim I.S. Auranofin promotes retinoic acid- or dihydroxyvitamin D3-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation. Br. J. Pharmacol. 2008, 154:1196-1205.
44. Kim I.S., Jin J.Y., Lee I.H., Park S.J. Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br. J. Pharmacol. 2004, 142:749-755.
45. Sokoloski J.A., Sartorelli A.C. Induction of the differentiation of HL-60 promyelocytic leukemia cells by nonsteroidal anti-inflammatory agents in combination with low levels of vitamin D3. Leuk. Res. 1998, 22:153-161.
46. Amano Y., Cho Y., Matsunawa M., Komiyama K., Makishima M. Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. J. Steroid Biochem. Mol. Biol. 2009, 114:144-151.
47. Zhang L., Nakaya K., Yoshida T., Kuroiwa Y. Induction by bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers. Cancer Res. 1992, 52:4634-4641.
48. Miyaura C., Abe E., Honma Y., Hozumi M., Nishii Y., Suda T. Cooperative effect of 1 alpha,25-dihydroxyvitamin D3 and dexamethasone in inducing differentiation of mouse myeloid leukemia cells. Arch. Biochem. Biophys. 1983, 227:379-385.
49. Steiner M., Priel I., Giat J., Levy J., Sharoni Y., Danilenko M. Carnosic acid inhibits proliferation and augments differentiation of human leukemic cells induced by 1,25-dihydroxyvitamin D3 and retinoic acid. Nutr. Can. 2001, 41:135-144.
50. Wang Q., Harrison J.S., Uskokovic M., Kutner A., Studzinski G.P. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia 2005, 19:1812-1817.
51. Zhang J., Harrison J.S., Uskokovic M., Danilenko M., Studzinski G.P. Silibinin can induce differentiation as well as enhance vitamin D(3)-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors. Hematol. Oncol. 2009.
52. Amir H., Karas M., Giat J., Danilenko M., Levy R., Yermiahu T., Levy J., Sharoni Y. Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr. Can. 1999, 33:105-112.
53. Shen M., Yen A. Nicotinamide cooperates with retinoic acid and 1,25-dihydroxyvitamin D(3) to regulate cell differentiation and cell cycle arrest of human myeloblastic leukemia cells. Oncology 2009, 76:91-100.
54. Kim S.H., Cho S.S., Simkhada J.R., Lee H.J., Kim S.W., Kim T.S., Yoo J.C. Enhancement of 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced HL-60 leukemia cell differentiation by Panax ginseng. Biosci. Biotechnol. Biochem. 2009, 73:1048-1053.
55. Sokoloski J.A., Hodnick W.F., Mayne S.T., Cinquina C., Kim C.S., Sartorelli A.C. Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-kappaB. Leukemia 1997, 11:1546-1553.
56. Kim S.H., Yoo J.C., Kim T.S. Nargenicin enhances 1,25-dihydroxyvitamin D(3)- and all-trans retinoic acid-induced leukemia cell differentiation via PKCbetaI/MAPK pathways. Biochem. Pharmacol. 2009, 77:1694-1701.
57. Yang J., Ikezoe T., Nishioka C., Ni L., Koeffler H.P., Yokoyama A. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo. Exp. Hematol. 2010.
58. Sokoloski J.A., Shyam K., Sartorelli A.C. Induction of the differentiation of HL-60 promyelocytic leukemia cells by curcumin in combination with low levels of vitamin D3. Oncol. Res. 1997, 9:31-39.
59. Kim S.H., Kim S.W., Choi S.J., Kim Y.C., Kim T.S. Enhancing effect of indirubin derivatives on 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells. Bioorg. Med. Chem. 2006, 14:6752-6758.
60. Makishima M., Okabe-Kado J., Honma Y. Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1alpha-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea. Br. J. Can. 1998, 77:33-39.
61. Irfan S.M., Bhurgri Y. Clinico-pathological features and outcomes in chronic phase chronic myeloid leukemia patients treated with hydroxyurea. Asian Pac. J. Can. Prev. 2009, 10:591-594.
62. Kang S.N., Chung S.W., Kim T.S. Capsaicin potentiates 1,25-dihydoxyvitamin D3- and all-trans retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells. Eur. J. Pharmacol. 2001, 420:83-90.
63. Berry D.M., Clark C.S., Meckling-Gill K.A. 1alpha, 25-dihydroxyvitamin D3 stimulates phosphorylation of IkappaBalpha and synergizes with TPA to induce nuclear translocation of NFkappaB during monocytic differentiation of NB4 leukemia cells. Exp. Cell Res. 2002, 272:176-184.
64. Bhatia M., Kirkland J.B., Meckling-Gill K.A. 1,25-dihydroxyvitamin D3 primes acute promyelocytic cells for TPA-induced monocytic differentiation through both PKC and tyrosine phosphorylation cascades. Exp. Cell Res. 1996, 222:61-69.
65. Kim D.S., Kim S.H., Song J.H., Chang Y.T., Hwang S.Y., Kim T.S. Enhancing effects of ceramide derivatives on 1,25-dihydroxyvitamin D(3)-induced differentiation of human HL-60 leukemia cells. Life Sci. 2007, 81:1638-1644.
66. Kim Y.R., Abraham N.G., Lutton J.D. Mechanisms of differentiation of U937 leukemic cells induced by GM-CSF and 1,25(OH)2 vitamin D3. Leuk. Res. 1991, 15:409-418.
67. Callens C., Coulon S., Naudin J., Radford-Weiss I., Boissel N., Raffoux E., Wang P.H., Agarwal S., Tamouza H., Paubelle E., et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J. Exp. Med. 2010, 207:731-750.
68. Seymour J.F., Gagel R.F. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993, 82:1383-1394.
69. Porojnicu A.C., Robsahm T.E., Ree A.H., Moan J. Season of diagnosis is a prognostic factor in Hodgkin's lymphoma: a possible role of sun-induced vitamin D. Br. J. Can. 2005, 93:571-574.
70. Hughes A.M., Armstrong B.K., Vajdic C.M., Turner J., Grulich A.E., Fritschi L., Milliken S., Kaldor J., Benke G., Kricker A. Sun exposure may protect against non-Hodgkin lymphoma: a case-control study. Int. J. Can. 2004, 112:865-871.
71. Kricker A., Armstrong B.K., Hughes A.M., Goumas C., Smedby K.E., Zheng T., Spinelli J.J., De Sanjose S., Hartge P., Melbye M., et al. Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the interlymph consortium. Int. J. Can. 2008, 122:144-154.
72. Lim U., Freedman D.M., Hollis B.W., Horst R.L., Purdue M.P., Chatterjee N., Weinstein S.J., Morton L.M., Schatzkin A., Virtamo J., et al. A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers. Int. J. Can. 2009, 124:979-986.
73. Polesel J., Talamini R., Montella M., Parpinel M., Dal Maso L., Crispo A., Crovatto M., Spina M., La Vecchia C., Franceschi S. Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. Ann. Oncol. 2006, 17:713-718.
74. Purdue M.P., Hartge P., Davis S., Cerhan J.R., Colt J.S., Cozen W., Severson R.K., Li Y., Chanock S.J., Rothman N., Wang S.S. Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma. Can. Causes Control 2007, 18:989-999.
75. Raimondi S., Johansson H., Maisonneuve P., Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009, 30:1170-1180.
76. Hickish T., Cunningham D., Colston K., Millar B.C., Sandle J., Mackay A.G., Soukop M., Sloane J. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br. J. Can. 1993, 68:668-672.
77. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179:1634-1647.
78. Consolini R., Pala S., Legitimo A., Crimaldi G., Ferrari S. Effects of vitamin D on the growth of normal and malignant B-cell progenitors. Clin. Exp. Immunol. 2001, 126:214-219.
79. Pepper C., Thomas A., Hoy T., Milligan D., Bentley P., Fegan C. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood 2003, 101:2454-2460.
80. Rigby W.F., Noelle R.J., Krause K., Fanger M.W. The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: a cell cycle analysis. J. Immunol. 1985, 135:2279-2286.
81. Niesvizky R., Coleman M., Mark T. Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant. Oncology (Williston Park) 2010, 24:14-21.
82. Ng A.C., Kumar S.K., Rajkumar S.V., Drake M.T. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am. J. Hematol. 2009, 84:397-400.
83. Badros A., Goloubeva O., Terpos E., Milliron T., Baer M.R., Streeten E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br. J. Haematol. 2008, 142:492-494.
84. Rossi J.F., Durie B.G., Duperray C., Braich T., Marion S.L., Pike J.W., Haussler M.R., Janbon C., Bataille R. Phenotypic and functional analysis of 1,25-dihydroxyvitamin D3 receptor mediated modulation of the human myeloma cell line RPMI 8226. Can. Res. 1988, 48:1213-1216.
85. Park W.H., Seol J.G., Kim E.S., Hyun J.M., Jung C.W., Lee C.C., Binderup L., Koeffler H.P., Kim B.K., Lee Y.Y. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br. J. Haematol. 2000, 109:576-583.
86. Kumagai T., O'Kelly J., Said J.W., Koeffler H.P. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J. Natl. Can. Inst. 2003, 95:896-905.
87. Ozdemir F., Esen N., Ovali E., Tekelioglu Y., Yilmaz M., Aydin F., Kavgaci H., Boruban C. Effects of dexamethasone, all-trans retinoic acid, vitamin D(3) and interferon-alpha on FO myeloma cells. Chemotherapy 2004, 50:190-193.
88. Wigington D.P., Strugnell S.A., Knutson J.C. Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells. Antican. Res. 2005, 25:1909-1917.
89. Elstner E., Linker-Israeli M., Umiel T., Le J., Grillier I., Said J., Shintaku I.P., Krajewski S., Reed J.C., Binderup L., Koeffler H.P. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Can. Res. 1996, 56:3570-3576.
90. Shimizu T., Taira N., Senou M., Takeda K. Involvement of diverse protein kinase C isoforms in the differentiation of ML-1 human myeloblastic leukemia cells induced by the vitamin D3 analogue KH1060 and the phorbol ester TPA. Can. Lett. 2002, 186:67-74.
91. Shimizu T., Kuromi A., Takeda K. Synergistic induction of gene expression during the differentiation into mature macrophage in human myeloblastic leukemia cells treated with TPA and KH1060. Leuk. Res. 2009, 33:803-809.
92. Pakkala I., Savli H., Knuutila S., Binderup L., Pakkala S. CB1093, a novel vitamin D analog; effects on differentiation and clonal growth on HL-60 and de novo leukemia cells. Leuk. Res. 1997, 21:321-326.
93. Park W.H., Seol J.G., Kim E.S., Jung C.W., Lee C.C., Binderup L., Koeffler H.P., Kim B.K., Lee Y.Y. Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. Exp. Cell Res. 2000, 254:279-286.
94. Puthier D., Bataille R., Barille S., Mellerin M.P., Harousseau J.L., Ponzio A., Robillard N., Wijdenes J., Amiot M. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Blood 1996, 88:4659-4666.
95. Jung C.W., Kim E.S., Seol J.G., Park W.H., Lee S.J., Kim B.K., Lee Y.Y. Antiproliferative effect of a vitamin D3 analog, EB1089, on HL-60 cells by the induction of TGF-beta receptor. Leuk. Res. 1999, 23:1105-1112.
96. James S.Y., Williams M.A., Kelsey S.M., Newland A.C., Colston K.W. The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells. Biochem. Pharmacol. 1997, 54:625-634.
97. Bondza-Kibangou P., Millot C., El Khoury V., Millot J.M. Antioxidants and doxorubicin supplementation to modulate CD14 expression and oxidative stress induced by vitamin D3 and seocalcitol in HL60 cells. Oncol. Rep. 2007, 18:1513-1519.
98. Seol J.G., Kim E.S., Park W.H., Jung C.W., Kim B.K., Lee Y.Y. Telomerase activity in acute myelogenous leukaemia: clinical and biological implications. Br. J. Haematol. 1998, 100:156-165.
99. Asou H., Koike M., Elstner E., Cambell M., Le J., Uskokovic M.R., Kamada N., Koeffler H.P. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 1998, 92:2441-2449.
100. Hisatake J., O'Kelly J., Uskokovic M.R., Tomoyasu S., Koeffler H.P. Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood 2001, 97:2427-2433.
101. Shabtay A., Sharabani H., Barvish Z., Kafka M., Amichay D., Levy J., Sharoni Y., Uskokovic M.R., Studzinski G.P., Danilenko M. Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia. Oncology 2008, 75:203-214.
102. Molnar I., Kute T., Willingham M.C., Schwartz G.G. 19-Nor-1alpha, 25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations. J. Steroid Biochem. Mol. Biol. 2004, 89-90:539-543.
103. Kumagai T., Shih L.Y., Hughes S.V., Desmond J.C., O'Kelly J., Hewison M., Koeffler H.P. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Can. Res. 2005, 65:2488-2497.
104. Binderup L., Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem. Pharmacol. 1988, 37:889-895.
105. Zhou J.Y., Norman A.W., Chen D.L., Sun G.W., Uskokovic M., Koeffler H.P. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc. Natl. Acad. Sci. USA 1990, 87:3929-3932.
106. Munker R., Kobayashi T., Elstner E., Norman A.W., Uskokovic M., Zhang W., Andreeff M., Koeffler H.P. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996, 88:2201-2209.
107. Hisatake J., Kubota T., Hisatake Y., Uskokovic M., Tomoyasu S., Koeffler H.P. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Can. Res. 1999, 59:4023-4029.
108. Ji Y., Wang X., Donnelly R.J., Uskokovic M.R., Studzinski G.P. Signaling of monocytic differentiation by a non-hypercalcemic analog of vitamin D3, 1,25(OH)2-5, 6 trans-16-ene-vitamin D3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways. J. Cell Physiol. 2002, 191:198-207.
109. Yoon J.S., Kim J.Y., Park H.K., Kim E.S., Ahn K.S., Yoon S.S., Cho C.G., Kim B.K., Lee Y.Y. Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia. Int. J. Oncol. 2008, 32:387-396.
110. Saito T., Okamoto R., Haritunians T., O'Kelly J., Uskokovic M., Maehr H., Marczak S., Jankowski P., Badr R., Koeffler H.P. Novel Gemini vitamin D(3) analogs have potent antitumor activity. J. Steroid Biochem. Mol. Biol. 2008, 112:151-156.
111. Ferrero D., Bruno B., Pregno P., Stefani S., Larizza E., Ciravegna G., Luraschi A., Vietti-Ramus G., Schinco P., Bazzan M., et al. Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk. Res. 1996, 20:867-876.
112. Ferrero D., Campa E., Dellacasa C., Campana S., Foli C., Boccadoro M. Differentiating agents+low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. Haematologica 2004, 89:619-620.
113. Koeffler H.P., Aslanian N., O'Kelly J. Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. Leuk. Res. 2005, 29:1259-1262.
114. Petrich A., Kahl B., Bailey H., Kim K., Turman N., Juckett M. Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. Leuk. Lymphoma 2008, 49:57-61.
115. Petrini M., Caracciolo F., Corini M., Valentini P., Sabbatini A.R., Grassi B. Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia: pilot study. Haematologica 1991, 76:200-203.
116. Slapak C.A., Desforges J.F., Fogaren T., Miller K.B. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am. J. Hematol. 1992, 41:178-183.
117. De Rosa L., Montuoro A., De Laurenzi A. Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3. Biomed. Pharmacother. 1992, 46:211-217.
118. Hellstrom E., Robert K.H., Gahrton G., Mellstedt H., Lindemalm C., Einhorn S., Bjorkholm M., Grimfors G., Uden A.M., Samuelsson J., et al. Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes. Eur. J. Haematol. 1988, 40:449-459.
119. Koeffler H.P., Hirji K., Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Can. Treat. Rep. 1985, 69:1399-1407.
120. Trump D.L., Deeb K.K., Johnson C.S. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Can. J. 2010, 16:1-9.
121. Takahashi T., Ichiba S., Okuno Y., Sugiyama H., Sakai Y., Imura H., Iho S., Hoshino T., Suzuki A., Okada T., et al. Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemias and myeloproliferative disorders. Rinsho Ketsueki 1989, 30:1-10.
122. Hellstrom E., Robert K.H., Samuelsson J., Lindemalm C., Grimfors G., Kimby E., Oberg G., Winqvist I., Billstrom R., Carneskog J., et al. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Eur. J. Haematol. 1990, 45:255-261.
123. Raina V., Cunningham D., Gilchrist N., Soukop M. Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. Br. J. Can. 1991, 63:463-465.
124. Blazsek I., Farabos C., Musset M., Goldschmidt E., Comisso M., Benavides M., Wang Z.Y., Labat M.L., Mathe G., Misset J.L. Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia. Biomed. Pharmacother. 1991, 45:169-177.
125. Motomura S., Kanamori H., Maruta A., Kodama F., Ohkubo T. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am. J. Hematol. 1991, 38:67-68.
126. Mellibovsky L., Diez A., Perez-Vila E., Serrano S., Nacher M., Aubia J., Supervia A., Recker R.R. Vitamin D treatment in myelodysplastic syndromes. Br. J. Haematol. 1998, 100:516-520.
127. Imseis R.E., Palmieri G.M., Holbert J.M., Leventhal M.R., Sebes J.I. Effect of calcitriol and pamidronate in multiple myeloma. Am. J. Med. Sci. 1999, 318:61-66.
128. Siitonen T., Timonen T., Juvonen E., Terava V., Kutila A., Honkanen T., Mikkola M., Hallman H., Kauppila M., Nylanden P., et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica 2007, 92:1119-1122.